Web1 dag geleden · Baird analyst Joel Beatty initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Outperform rating and announces Price Target of $44. WebRobert W. Baird analyst Joel Beatty reiterated a Buy rating on Geron ( GERN - Research Report) on October 31 and set a price target of $4.00. The companys shares closed …
ARGEN-X 2024, op naar de 450 » Pagina: 9 - IEX.nl
WebPHAS is currently covered by 3 analysts with average potential upside of $6.73 (95.28%) backed by 12 price targets and 20 ratings. Documented since 13-Nov-2024. Most recent stock forecast was given by JOEL BEATTY from BAIRD on 25-Aug-2024.. Highest price target for PHAS is 4, Lowest price target is 4, average price target is 4. WebARGX is currently covered by 21 analysts with average potential upside of $46.12 (18.04%) backed by 119 price targets and 173 ratings. Documented since 12-Jun-2024. Analyst's average stock valuation to be materialised ratio is 69.78% with an average time for price targets to be met of 138.67 days. hoffman ford service harrisburg pa
Derby d
WebOthers named Joel Beatty. Joel Beatty ... Senior Research Analyst - Biotechnology at Baird New York, NY. Joel Beatty Principal Investigator at Arcus Biosciences ... WebArrowhead Pharmaceuticals Inc Stock Forecast, Predictions & Price Target Overview Forecast Earnings Dividend Ownership Analyst price target for ARWR All Analysts Top … Web15 mrt. 2024 · Baird analyst Joel Beatty lowered the firm's price target on BeyondSpring to $4 from $11 and keeps an Outperform rating on the shares. The analyst said the target reduction comes after BeyondSpring confirmed that the NDA filing for plinabulin to treat chemotherapy-induced neutropenia has been withdrawn in China. hoffman ford service ct